Group telehealth program to help adults with chronic graft-versus-host disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

HORIZONS is a multidisciplinary, group-based telehealth program designed for adults living with moderate to severe chronic graft-versus-host disease. In this randomized trial, about 350 allogeneic hematopoietic cell transplant survivors will be assigned to HORIZONS plus usual care or to minimally enhanced usual care and followed for up to 18 weeks. The intervention delivers structured group sessions in English or Spanish that target self-management, symptom coping, and psychosocial support. Investigators will measure quality of life, psychosocial distress, and identify barriers and facilitators to implementing HORIZONS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥ 18 years) who have undergone allogeneic HCT
* Have moderate to severe cGVHD based on patient-report
* Have ability to participate in English or Spanish language group telehealth intervention.

Exclusion Criteria:

* Patients with mild cGVHD based on their self-report.
* Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.
* Patients with active relapsed disease requiring therapy.

Where it's running

• University of Miami Sylvester Comprehensive Cancer Center
  Miami, Florida, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Areej El-Jawahri MD — Massachusetts General Hospital
• Study coordinator: Lara Traeger PhD
• Email: ltraeger@miami.edu
• Phone: 304-284-3012

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Ruxolitinib to prevent complications after haploidentical stem cell transplants

  This study is testing if the drug Ruxolitinib can help prevent complications like graft-versus-host disease in patients receiving stem cell transplants from partially matched donors.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06008808

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• Ruxolitinib for Graft-Versus-Host Disease in Clinical Practice

  This study tests how well Jakavi (ruxolitinib) works and how safe it is for people with acute or chronic GVHD being treated in real-world medical settings.

  Recruiting Novartis · Tokyo · NCT07594587

• Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant

  This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07572669

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.